Electroconvulsive therapy for the acute management of severe agitation in dementia (ECT-AD): A modified study protocol.
Maria I LapidJulia MerrillMartina MuellerAdriana P HermidaLouis NykampJason AndrusHeela AziziPaula BoltonNana BonsuRaphael BragaCatherine R DillonDonna EcklesdaferDarci EvansDavid HarperHannah L HeintzSehba Hussain-KrauterOlivia HolzgenDaniel HumphreySalima JiwaniEmily K JohnsonSimran KangJanelle KassienJonathan KimRebecca G KnappSimon KungNeil KremenKendra LeJack MahdasianTaylor MarzoukJared D MasrudJefferson MattinglyDawn MillerSandeep R PagaliRegan E PatrickPatricio Riva PosseCristina PritchettAniqa RahmanSwapnil RathCara RoczniakTeresa A RummansSohag SanghaniSteve SeinerLeAnn SmartEvan TomaschekValeriya TsygankovaLori VanderSchuur-WhiteMonica P WaltonJames WilkinsApril WilliamsSarah M WilliamsGeorge PetridesBrent P ForesterPublished in: PloS one (2024)
The transition of the ECT-AD study design from an RCT to open-label design exemplifies adaptive research methodologies in response to real-world challenges. Data from both the RCT and open-label phases of the study will provide a unique perspective on the role of ECT in managing severe treatment-refractory agitation in dementia, potentially influencing future clinical practices and research approaches.
Keyphrases
- open label
- study protocol
- mild cognitive impairment
- clinical trial
- phase ii
- phase ii study
- phase iii
- drug induced
- cognitive impairment
- early onset
- randomized controlled trial
- healthcare
- primary care
- liver failure
- electronic health record
- respiratory failure
- big data
- current status
- aortic dissection
- deep learning
- hepatitis b virus
- mechanical ventilation